| Tue, 26 Sep 2017 11:20:36: | Despite hope and hype, Axovant serves up another failed Alzheimer’s med
|
| Mon, 25 Sep 2017 15:45:31: | Eligo raises $20M to take bacteria-killing CRISPR drug into clinic
|
| Mon, 25 Sep 2017 12:26:46: | Boost for Exelixis as partner Daiichi Sankyo cues up hypertension drug filing
|
| Mon, 25 Sep 2017 11:57:11: | AstraZeneca, NewLink pen PD-L1 and IDO combination pact
|
| Mon, 25 Sep 2017 11:05:15: | Sensor captures bacteria's movements to measure antibiotic efficacy
|
| Mon, 25 Sep 2017 10:04:06: | FDA rejects Johnson & Johnson’s rheumatoid arthritis drug sirukumab on safety grounds, demands more data
|
| Mon, 25 Sep 2017 09:09:48: | Pfizer launches upstart with $103M, phase 3-ready drugs
|
| Fri, 22 Sep 2017 12:43:43: | AbbVie pairs up another ADC cancer drug with Bristol-Myers Squibb's Opdivo
|
| Fri, 22 Sep 2017 08:05:43: | Phase 3 flop puts Versartis on life support
|
| Fri, 22 Sep 2017 07:17:44: | Nestlé to ax up to 450 skin health R&D jobs, exit facility
|
| Thu, 21 Sep 2017 18:37:08: | Chutes & Ladders—Ex-GlaxoSmithKline CEO Witty joins venture capital
|
| Thu, 21 Sep 2017 13:39:03: | EuroBiotech Report—Bavarian Nordic, Nabriva, Immunocore, Glythera-Iontas and Sanofi
|
| Thu, 21 Sep 2017 13:10:06: | Celgene-backed FLX picks CCR4 antagonist for clinical trials
|
| Thu, 21 Sep 2017 12:05:14: | Janssen deal gives new kid in town Provention two immune candidates
|
| Thu, 21 Sep 2017 10:35:00: | First biotech emerges from Garabedian’s accelerator armed with $10M, plans to tackle autoimmune diseases
|
| Wed, 20 Sep 2017 16:27:05: | Sanofi and NIH chart early success with 3-part antibody against HIV
|
| Wed, 20 Sep 2017 13:31:12: | Lightstone goes over target with new $250M biotech fund
|
| Wed, 20 Sep 2017 13:09:48: | China’s WuXi, Johnson & Johnson-backed XW Labs lands $17.5M series B
|
| Wed, 20 Sep 2017 12:56:14: | Arcus' cancer portfolio attracts $35M option deal from Japan's Taiho
|
| Wed, 20 Sep 2017 12:48:34: | How poliovirus unleashes an attack on glioblastoma
|
| Wed, 20 Sep 2017 12:36:34: | Glythera taps Iontas for antibodies to guide next-generation ADCs
|
| Wed, 20 Sep 2017 12:26:44: | Alnylam’s patisiran hits all endpoints in critical phase 3
|
| Tue, 19 Sep 2017 13:14:45: | Aerie raids Alcon again, returning this time with an R&D VP
|
| Tue, 19 Sep 2017 12:42:52: | Acceleron takes back drug rights from Celgene to start pulmonary push
|
| Tue, 19 Sep 2017 10:48:37: | Ex-GlaxoSmithKline CEO Witty joins Hatteras as venture partner
|
